Immune Checkpoint Inhibitors Demonstrate Safety and Efficacy for NSCLC Treatment in HIV-Positive Patients
Key Insights
A comprehensive review of five studies involving 274 patients demonstrates that immune checkpoint inhibitors are safe and effective for treating non-small cell lung cancer in people living with HIV (search).
Patients with HIV (search) showed comparable progression-free survival, overall response rates, and overall survival outcomes to HIV-negative control groups, with similar rates of immune-related adverse events.
The findings address a critical knowledge gap since HIV (search)-positive patients are typically excluded from pivotal clinical trials, providing real-world evidence for clinical decision-making.
A new systematic review provides compelling evidence that immune checkpoint inhibitors (ICIs) can be safely and effectively used to treat non-small cell lung cancer (NSCLC) in patients living with HIV (search), addressing a significant gap in clinical knowledge for this vulnerable population.
The comprehensive analysis, published in HIV (search) Medicine, examined five studies encompassing patients with both HIV and NSCLC who received checkpoint inhibitor therapy. The research is particularly significant given that people living with HIV are routinely excluded from pivotal cancer immunotherapy trials, leaving clinicians with limited guidance for treatment decisions.
Real-World Evidence Supports Treatment Efficacy
The largest study in the review, conducted by the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV (search)-International Consortium, retrospectively analyzed 111 patients with both HIV and NSCLC. Among these, 61 patients with metastatic NSCLC were matched with an HIV-negative control group, all receiving at least one dose of an ICI.
The results demonstrated no significant differences in progression-free survival, overall response rate, or overall survival between HIV (search)-positive and HIV-negative patients. Immune-related adverse events occurred in 22% of people living with HIV compared with 20% in the control group, indicating comparable safety profiles.
Consistent Outcomes Across Multiple Studies
A dedicated nivolumab study involving 16 HIV (search)-positive patients with advanced NSCLC showed a disease control rate of 62.5% after eight weeks of treatment. The median progression-free survival reached 3.4 months, with median overall survival of 10.9 months. All patients were virally suppressed on antiretroviral therapy and had received at least one prior chemotherapy cycle. Only mild to moderate treatment-related adverse effects were reported.
The French CANCERVIH registry contributed data from 21 patients with HIV (search) and NSCLC, where 55% received ICIs as second-line treatment. Nivolumab monotherapy was the most commonly used agent. All participants were virally suppressed and received either pembrolizumab or nivolumab, achieving a median survival of 10.7 months and disease control rate of 42.9%.
Broader HIV-Positive Lung Cancer Population
The OncoVIHAC ANRS CO24 prospective observational cohort study included 65 patients with lung cancer and HIV (search), regardless of viral suppression status. The estimated 18-month overall survival was 36.4%, with progression-free survival of 25.5%. Grade 3 or higher immune-related adverse events occurred in 15.4% of patients. Importantly, most patients who were virally suppressed at study initiation remained virally suppressed throughout treatment.
Clinical Practice Implications
The review's authors concluded that ICIs were safe and effective for people living with both HIV (search) and NSCLC, but emphasized important clinical considerations. "Close interdisciplinary collaboration between oncology and HIV care providers is essential—particularly regarding ART management, potential drug interactions, and regular monitoring of immune status and HIV viral load," they noted.
The findings suggest that checkpoint blockade can be integrated into oncology care for NSCLC without unique safety signals attributable to HIV (search) status. However, careful attention to baseline immune function, adherence to antiretroviral therapy, and close assessment for immune-related adverse events remains crucial.
Study Limitations and Future Directions
The researchers acknowledged several limitations, including the predominantly retrospective nature of the data and small sample sizes across all studies. Additionally, data on dual checkpoint blockade combinations were lacking, representing an area for future investigation.
The review underscores the critical need for broader inclusion of people living with HIV (search) in future lung cancer immunotherapy trials, as well as dedicated HIV-specific studies to refine patient selection criteria and clarify long-term outcomes. For current clinical practice, the balance of evidence supports offering immune checkpoint inhibitors to eligible NSCLC patients living with HIV, accompanied by routine monitoring and coordinated care between oncology and HIV specialists.